VEGF-A Levels in Multiple Sclerosis Patients
Author Information
Author(s): Ellen Iacobaeus, Petra Amoudruz, Mikael Ström, Mohsen Khademi, Lou Brundin, Jan Hillert, Ingrid Kockum, Vivianne Malmström, Tomas Olsson, Emma Tham, Fredrik Piehl
Primary Institution: Karolinska Institute
Hypothesis
The study investigates the role of VEGF-A in the transition from relapsing-remitting multiple sclerosis (RRMS) to secondary progressive multiple sclerosis (SPMS).
Conclusion
VEGF-A expression is reduced in both cerebrospinal fluid and peripheral blood mononuclear cells of MS patients, particularly in those with SPMS, suggesting its potential role as a biomarker.
Supporting Evidence
- VEGF-A mRNA expression was significantly reduced in MS patients compared to controls.
- SPMS patients showed a distinct reduction in VEGF-A levels in peripheral blood compared to RRMS and controls.
- VEGF-A expression levels were restored by natalizumab treatment in some patients.
- Monocytes were identified as the primary source of VEGF-A expression in peripheral blood.
Takeaway
This study found that a substance called VEGF-A is lower in the blood of people with a certain type of multiple sclerosis, which might help doctors understand the disease better.
Methodology
The study analyzed VEGF-A mRNA expression in peripheral blood mononuclear cells and cerebrospinal fluid from MS patients and controls using real-time PCR.
Limitations
The study did not find significant associations between VEGF-A gene variants and MS risk, indicating a need for larger studies.
Participant Demographics
The study included 128 RRMS patients, 55 SPMS patients, and 116 controls, with a mix of genders and ages.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website